[go: up one dir, main page]

AR055105A1 - Inhibidores macrociclicos del virus de la hepatitis c - Google Patents

Inhibidores macrociclicos del virus de la hepatitis c

Info

Publication number
AR055105A1
AR055105A1 ARP060103307A ARP060103307A AR055105A1 AR 055105 A1 AR055105 A1 AR 055105A1 AR P060103307 A ARP060103307 A AR P060103307A AR P060103307 A ARP060103307 A AR P060103307A AR 055105 A1 AR055105 A1 AR 055105A1
Authority
AR
Argentina
Prior art keywords
substituents
optionally substituted
ring
inhibitors
optionally
Prior art date
Application number
ARP060103307A
Other languages
English (en)
Original Assignee
Tibotec Pharm Ltd
Medivir Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37028035&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR055105(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tibotec Pharm Ltd, Medivir Ab filed Critical Tibotec Pharm Ltd
Publication of AR055105A1 publication Critical patent/AR055105A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Inhibidores de la replicacion del VHC de formula (1) los N-oxidos, sales y formas estereoquímicamente isoméricas de éstos, donde cada línea de puntos ( representada por ----) representa un doble enlace opcional; X es N, CH y donde X lleva un doble enlace es C; R1 es arilo o un sistema anular saturado, parcialmente insaturado o completamente insaturado de 5 o 6 miembros o bicíclico heterocíclico de 9 a 12 miembros donde dicho sistema anular contiene un N, y en forma opcional 1 a 3 heteroátomos adicionales seleccionados del grupo que consiste en O, S y N, y donde el resto de los miembros del anillo son átomos de C, donde dicho sistema anular puede estar sustituido en forma opcional en cualquier átomo de Co N del anillo con 1, 2, 3 o 4 sustituyentes, L es un enlace directo, -O-, -O-alcandiilo C1-4-, -O-C(=O)-, -O-C(=O)-NR4a- u - O-C(=O)-NR4a alcandiilo C1-4; R2 es H, -OR5, -C(=O)OR5, -C(=O)R6, -C(=O)NR4aR4b, -C(=O)NHR4c, -NR4aR4b, -NHR4c, -NR4aSOpNR4aR4b, -NR4aSOpR7 o B(OR5)2, R3 es H, y cuando X es C o CH, R3 también puede ser alquilo C1-6; n es 3, 4, 5, o 6; p es 1 o 2; arilo es fenilo, naftilo, indanilo, o 1,2,3,4-tetrahidronaftilo, cada uno de los cuales puede estar sustituido en forma opcional con 1, 2 o 3 sustituyentes; Het es un anillo heterocíclico saturado, parcialmente insaturado o completamente insaturado de 5 o 6 miembros que contiene 1 a 4 heteroátomos seleccionados cada uno en forma independiente de N, O y S, condensados en forma opcional con un anillo bencénico, y donde el grupo Het como un todo puede estar sustituido en forma opcional con 1, 2 o 3 sustituyentes; composiciones farmacéuticas que contienen compuestos (1) y procesos para preparar compuestos (1). También se proporcionan combinaciones biodisponibles de los inhibidores del VHC de formula (1) con ritonavir.
ARP060103307A 2005-07-29 2006-07-28 Inhibidores macrociclicos del virus de la hepatitis c AR055105A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05107068 2005-07-29
EP05107414 2005-08-11

Publications (1)

Publication Number Publication Date
AR055105A1 true AR055105A1 (es) 2007-08-08

Family

ID=37028035

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103307A AR055105A1 (es) 2005-07-29 2006-07-28 Inhibidores macrociclicos del virus de la hepatitis c

Country Status (12)

Country Link
US (2) US20100120855A1 (es)
EP (1) EP1912996B1 (es)
JP (1) JP5426164B2 (es)
CN (1) CN101273042B (es)
AR (1) AR055105A1 (es)
BR (1) BRPI0614621A2 (es)
DK (1) DK1912996T3 (es)
ES (1) ES2389964T3 (es)
MY (1) MY144895A (es)
RU (1) RU2441870C2 (es)
TW (1) TWI383980B (es)
WO (1) WO2007014920A1 (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
SI1713823T1 (sl) 2004-01-30 2010-04-30 Medivir Ab Inhibitorji HCV NS-3 serin proteaze
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
US8183277B2 (en) * 2005-07-29 2012-05-22 Tibotec Pharmaceuticals Ltd. Macrocylic inhibitors of hepatitis C virus
DK1912997T3 (da) * 2005-07-29 2012-01-02 Tibotec Pharm Ltd Makrocycliske inhibitorer af hepatitis C virus
AU2006274862B2 (en) * 2005-07-29 2012-03-22 Medivir Ab Macrocyclic inhibitors of hepatitis C virus
PE20070343A1 (es) * 2005-07-29 2007-05-12 Medivir Ab Inhibidores macrociclicos del virus de la hepatitis c
DE602006019883D1 (de) * 2005-07-29 2011-03-10 Medivir Ab Makrocyclische inhibitoren des hepatitis-c-virus
PE20070210A1 (es) * 2005-07-29 2007-04-16 Tibotec Pharm Ltd Compuestos macrociclicos como inhibidores del virus de hepatitis c
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7935670B2 (en) 2006-07-11 2011-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2008019289A2 (en) 2006-08-04 2008-02-14 Enanta Pharmaceuticals, Inc. Tetrazolyl macrocyclic hepatitis c serine protease inhibitors
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US8383583B2 (en) 2007-10-26 2013-02-26 Enanta Pharmaceuticals, Inc. Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
US8426360B2 (en) * 2007-11-13 2013-04-23 Enanta Pharmaceuticals, Inc. Carbocyclic oxime hepatitis C virus serine protease inhibitors
EP2219454A4 (en) 2007-11-14 2012-05-30 Enanta Pharm Inc HEMMER OF MACROCYCLIC TETRAZOLYL HEPATITIS C SERIN PROTEASE
WO2009070692A1 (en) 2007-11-29 2009-06-04 Enanta Pharmaceuticals, Inc. C5-substituted, proline-derived, macrocyclic hepatitis c serine protease inhibitors
US8273709B2 (en) 2007-12-14 2012-09-25 Enanta Pharmaceuticals, Inc. Triazole-containing macrocyclic HCV serine protease inhibitors
US8283309B2 (en) 2007-12-20 2012-10-09 Enanta Pharmaceuticals, Inc. Bridged carbocyclic oxime hepatitis C virus serine protease inhibitors
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
JP5490778B2 (ja) 2008-03-20 2014-05-14 エナンタ ファーマシューティカルズ インコーポレイテッド Ｃ型肝炎ウイルス阻害剤としてのフッ素化大環状化合物
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP5529120B2 (ja) 2008-05-29 2014-06-25 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎ウイルス阻害剤
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
SG172359A1 (en) 2008-12-23 2011-07-28 Pharmasset Inc Nucleoside phosphoramidates
NZ593647A (en) 2008-12-23 2013-08-30 Gilead Pharmasset Llc Synthesis of purine nucleosides
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
KR20110136819A (ko) * 2009-02-27 2011-12-21 시가 테크놀로지스, 인크. 뎅기 바이러스 감염의 치료 및 예방을 위한 티에노피리딘 유도체
US8377962B2 (en) 2009-04-08 2013-02-19 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
US9284307B2 (en) 2009-08-05 2016-03-15 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors
UA104517C2 (uk) * 2010-03-10 2014-02-10 Ебботт Леборетріз Тверда композиція, що є корисною в лікуванні інфекції вірусу гепатиту с, та способи її одержання
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
TW201136945A (en) 2010-03-31 2011-11-01 Pharmasset Inc Purine nucleoside phosphoramidate
JP2013527145A (ja) 2010-03-31 2013-06-27 ギリード・ファーマセット・エルエルシー リン含有活性化剤の立体選択的合成
US8759527B2 (en) 2010-08-25 2014-06-24 Bayer Cropscience Ag Heteroarylpiperidine and -piperazine derivatives as fungicides
PT3042910T (pt) 2010-11-30 2019-04-16 Gilead Pharmasset Llc 2'-espiro-nucleósidos para utilização na terapia da hepatite c
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8962810B2 (en) 2011-06-16 2015-02-24 AB Pharma Ltd. Macrocyclic heterocyclic compound for inhibiting hepatitis C virus and preparation and use thereof
CA2840242C (en) 2011-09-16 2019-03-26 Gilead Sciences, Inc. Methods for treating hcv
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
MX360452B (es) 2012-10-19 2018-11-01 Bristol Myers Squibb Co Inhibidores del virus de la hepatitis c.
EP2914598B1 (en) 2012-11-02 2017-10-18 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2914613B1 (en) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
KR20200060782A (ko) 2013-01-31 2020-06-01 길리애드 파마셋 엘엘씨 두 항바이러스 화합물의 병용 제형물
JP6342922B2 (ja) 2013-03-07 2018-06-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
EP3650014B1 (en) 2013-08-27 2021-10-06 Gilead Pharmasset LLC Combination formulation of two antiviral compounds

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2549063B1 (fr) * 1983-07-13 1985-10-25 Rhone Poulenc Sante Nouveaux derives de synergistines, leur preparation et les compositions pharmaceutiques qui les contiennent
EP1302468B1 (en) 1992-12-29 2008-12-17 Abbott Laboratories Processes and intermediates for manufacturing retroviral protease inhibiting compounds
US5508272A (en) * 1993-06-15 1996-04-16 Bristol-Myers Squibb Company Compounds containing a fused bicycle ring and processes therefor
IL110752A (en) * 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
IL111991A (en) * 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US6054472A (en) * 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
US5807876A (en) * 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
IL126674A (en) 1996-04-23 2005-08-31 Vertex Pharma Use of cyclic and heterocyclic compounds for preparing pharmaceutical compositions inhibiting impdh activity, pharmaceutical compositions containing the same and novel thiazole and oxazole urea derivatives
UA79749C2 (en) 1996-10-18 2007-07-25 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
ATE244717T1 (de) 1997-03-14 2003-07-15 Vertex Pharma Inhibitoren des impdh-enzyms
IL134233A0 (en) 1997-08-11 2001-04-30 Boehringer Ingelheim Ca Ltd Hepatitis c inhibitor peptide analogues
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
EP1964561A1 (en) * 1999-03-19 2008-09-03 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
UA74546C2 (en) * 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
JP4778665B2 (ja) 2000-08-30 2011-09-21 パナソニック株式会社 プラズマディスプレイ表示装置の製造方法
CA2481369C (en) * 2002-04-11 2012-07-10 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease
CN1771050A (zh) 2003-02-07 2006-05-10 益安药业 丙型肝炎丝氨酸蛋白酶的大环抑制剂
DE602004019518D1 (de) * 2003-04-16 2009-04-02 Bristol Myers Squibb Co Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus
US7125845B2 (en) * 2003-07-03 2006-10-24 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis C serine protease inhibitors
CN103145715B (zh) 2003-10-14 2016-08-03 F·霍夫曼-罗须公司 作为hcv复制抑制剂的巨环羧酸和酰基磺酰胺
US7309708B2 (en) * 2003-11-20 2007-12-18 Birstol-Myers Squibb Company Hepatitis C virus inhibitors
SI1713823T1 (sl) 2004-01-30 2010-04-30 Medivir Ab Inhibitorji HCV NS-3 serin proteaze

Also Published As

Publication number Publication date
WO2007014920A1 (en) 2007-02-08
RU2008107738A (ru) 2009-09-10
TWI383980B (zh) 2013-02-01
US8754105B2 (en) 2014-06-17
BRPI0614621A2 (pt) 2011-04-12
US20110237621A1 (en) 2011-09-29
CN101273042A (zh) 2008-09-24
TW200800945A (en) 2008-01-01
JP5426164B2 (ja) 2014-02-26
EP1912996B1 (en) 2012-06-20
DK1912996T3 (da) 2012-09-17
EP1912996A1 (en) 2008-04-23
RU2441870C2 (ru) 2012-02-10
ES2389964T3 (es) 2012-11-05
JP2009502883A (ja) 2009-01-29
CN101273042B (zh) 2013-11-06
MY144895A (en) 2011-11-30
US20100120855A1 (en) 2010-05-13

Similar Documents

Publication Publication Date Title
AR055105A1 (es) Inhibidores macrociclicos del virus de la hepatitis c
EA200800478A1 (ru) Макроциклические ингибиторы вируса гепатита с
AR086019A1 (es) COMPUESTOS DE PIRROLO SULFONAMIDA PARA MODULACION DE LA ACTIVIDAD DEL RECEPTOR HUERFANO g RELACIONADO AL RECEPTOR NUCLEAR HUERFANO RAR (RORg, NR1F3) Y PARA EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS Y AUTOINMUNES CRONICAS
UY29703A1 (es) "inhibidores macrocíclicos del virus de la hepatitis c"
CL2016002942A1 (es) Nuevos derivados de pirazolina pirimidina y su uso como inhibidores de malt1
PE20181298A1 (es) Inhibidores de bromodominio bivalentes y usos de los mismos
ES2746839T3 (es) Derivados de pirimidina y triazina y su uso como inhibidores de AXL
AR105893A1 (es) Derivados del anillo (hetero) aromático sustituidos con carboxi como inhibidores de xantina oxidasa y del transportador 1 del anión urato
AR072726A1 (es) Derivados de indol macrociclicos utiles como inhibidores del virus de la hepatitis c
AR079164A1 (es) Derivados heterociclicos de indol, composiciones farmaceuticas que los comprenden y uso de los mismos para la profilaxis o tratamiento de enfermedades alergicas, inflamatorias y/o autoinmunes.
AR088449A1 (es) Benzilindazoles sustituidos
AR078164A1 (es) Derivados de isoxazolidina, proceso para preparar dichos compuestos y composiciones farmaceuticas que los comprenden
ES2630079T3 (es) Moduladores de la ruta del complemento y usos de los mismos
ES2684517T3 (es) Compuestos de heterociclilo como inhibidores de MEK
PE20191245A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
PE20220567A1 (es) Nuevos derivados piperidinilo, un proceso para su preparacion y composiciones farmaceuticas que los contienen
PE20161405A1 (es) Analogos de cortistatina y sintesis y usos de los mismos
AR077695A1 (es) Derivados de pirimidina como inhibidores del factor ixa
AR071652A1 (es) Derivados 2- fenil-piridina substituidos
PE20190968A1 (es) Compuestos de heterociclo tetraciclicos utiles como inhibidores de la integrasa del vih
PE20212325A1 (es) Derivados de pirimidona de anillo fusionado para uso en el tratamiento de infeccion por vhb o enfermedades inducidas por vhb
AR108778A1 (es) Compuestos antibacterianos
AR106515A1 (es) Sililfenoxiheterociclos trisustituidos y análogos
PE20190339A1 (es) 1h-pirazolo[4,3-b] piridinas como inhibidores de pde1
PE20200932A1 (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3

Legal Events

Date Code Title Description
FB Suspension of granting procedure